Lise Mørkved Helsingen

• Helsingen, Lise Mørkved; Langeland, Eline Aurvoll; Pisani, Synne Eline Rotihaug; Vandvik, Per Olav; Haavardsholm, Espen A. & Malt, Ulrik Fredrik [Show all 10 contributors for this article] (2024). Glansbilder av nasjonale faglige retningslinjer fra Helsedirektoratet. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 144(5). doi: 10.4045/tidsskr.24.0141.
• Bretthauer, Michael; Wieszczy, Paulina; Løberg, Magnus; Kamiński, Michał Filip; Werner, Tarjei Fiskergård & Helsingen, Lise Mørkved [Show all 10 contributors for this article] (2023). Estimated Lifetime Gained with Cancer Screening Tests: A Meta-Analysis of Randomized Clinical Trials. JAMA Internal Medicine. ISSN 2168-6106. 183(11), p. 1196–1203. doi: 10.1001/jamainternmed.2023.3798.
• Langeland, Eline Aurvoll; Pisani, Synne E. R.; Kalager, Mette; Bretthauer, Michael & Helsingen, Lise Mørkved (2023). Følger Helsedirektoratets retningslinjer internasjonale standarder for troverdighet? Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(14). doi: 10.4045/tidsskr.23.0110. Full text in Research Archive
• Zeng, Linan; Helsingen, Lise Mørkved; Bretthauer, Michael; Agoritsas, Thomas; Vandvik, Per Olav & Mustafa, Reem A. [Show all 15 contributors for this article] (2023). A novel framework for incorporating patient values and preferences in making guideline recommendations: guideline panel surveys. Journal of Clinical Epidemiology. ISSN 0895-4356. doi: 10.1016/j.jclinepi.2023.07.003.
• Zeng, Linan; Li, Shelly-Anne; Yang, Mengting; Yan, Lijiao; Helsingen, Lise Mørkved & Bretthauer, Michael [Show all 15 contributors for this article] (2023). Qualitative study of guideline panelists: innovative surveys provided valuable insights regarding patient values and preferences. Journal of Clinical Epidemiology. ISSN 0895-4356. doi: 10.1016/j.jclinepi.2023.07.014.
• Jodal, Henriette C.; Wieszczy, Paulina; Klotz, Dagmar; Herfindal, Magnhild; Barua, Ishita & Tag, Petter [Show all 13 contributors for this article] (2023). A Comparison of Risk Classification Systems of Colorectal Adenomas: A Case-Cohort Study. Gastroenterology. ISSN 0016-5085. 165, p. 483–491. doi: 10.1053/j.gastro.2023.04.028. Full text in Research Archive
• Holme, Øyvind; Kalager, Mette; Bretthauer, Michael; Adami, Hans Olov; Helsingen, Lise Mørkved & Løberg, Magnus (2023). Ongoing Trials Will Not Determine the Comparative Effectiveness of Colorectal Cancer Screening Tests. Gastroenterology. ISSN 0016-5085. 164(6), p. 856–860. doi: 10.1053/j.gastro.2020.02.071.
• Yu, Jingru; Refsum, Erle; Wieszczy, Paulina; Helsingen, Lise Mørkved; Perrin, Vera & Högdén, Amanda [Show all 12 contributors for this article] (2023). Risk of malignant lymphomas in patients with inflammatory bowel disease: a population-based cohort study. BMJ open gastroenterology. ISSN 2054-4774. 10(1). doi: 10.1136/bmjgast-2022-001037.
• Yu, Jingru; Refsum, Erle; Perrin, Vera; Helsingen, Lise Mørkved; Wieszczy, Paulina & Løberg, Magnus [Show all 11 contributors for this article] (2022). Inflammatory bowel disease and risk of adenocarcinoma and neuroendocrine tumors in the small bowel. Annals of Oncology. ISSN 0923-7534. p. 1–8. doi: 10.1016/j.annonc.2022.02.226.
• Yu, Jingru; Refsum, Erle; Helsingen, Lise Mørkved; Folseraas, Trine; Ploner, Alexander & Wieszczy, Paulina [Show all 15 contributors for this article] (2022). Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study. United European Gastroenterology Journal (UEG Journal). ISSN 2050-6406. 10(2), p. 212–224. doi: 10.1002/ueg2.12204. Full text in Research Archive
• Usher-Smith, Juliet A.; Mills, Katie M.; Riedinger, Christiane; Saunders, Catherine L.; Helsingen, Lise Mørkved & Lytvyn, Lyubov [Show all 11 contributors for this article] (2021). The impact of information about different absolute benefits and harms on intention to participate in colorectal cancer screening: A think-aloud study and online randomised experiment. PLOS ONE. ISSN 1932-6203. 16(2). doi: 10.1371/journal.pone.0246991.
• Helsingen, Lise Mørkved; Løberg, Magnus; Refsum, Erle; Gjøstein, Dagrun Kyte; Wieszczy, Paulina & Olsvik, Ørjan [Show all 16 contributors for this article] (2021). Covid-19 transmission in fitness centers in Norway - a randomized trial. BMC Public Health. ISSN 1471-2458. 21, p. 1–9. doi: 10.1186/s12889-021-12073-0. Full text in Research Archive
• Jodal, Henriette C.; Klotz, Dagmar; Herfindal, Magnhild; Barua, Ishita; Tag, Petter & Helsingen, Lise Mørkved [Show all 12 contributors for this article] (2021). Long-term colorectal cancer incidence and mortality after adenoma removal in women and men. Alimentary Pharmacology and Therapeutics. ISSN 0269-2813. p. 1–10. doi: 10.1111/apt.16686.
• Juul, Frederik E.; Jodal, Henriette C.; Barua, Ishita; Refsum, Erle; Olsvik, Ørjan & Helsingen, Lise Mørkved [Show all 10 contributors for this article] (2021). Mortality in Norway and Sweden during the COVID-19 pandemic. Scandinavian Journal of Public Health. ISSN 1403-4948. p. 1–8. doi: 10.1177/14034948211047137. Full text in Research Archive
• Zeng, Linan; Helsingen, Lise M.; Nampo, Fernando Kenji; Wang, Yuting; Yao, Linag & Siemieniuk, Reed Alexander [Show all 8 contributors for this article] (2020). How do cancer screening guidelines trade off benefits versus harms and burdens of screening? A systematic survey . BMJ Open. ISSN 2044-6055. doi: 10.1136/bmjopen-2020-038322.
• Helsingen, Lise M.; Zeng, Linan; Siemieniuk, Reed A.C.; Lytvyn, Lyubov; Vandvik, Per Olav & Agoritsas, Thomas [Show all 8 contributors for this article] (2020). Establishing thresholds for important benefits considering the harms of screening interventions. BMJ Open. ISSN 2044-6055. 10:e037854(12), p. 1–9. doi: 10.1136/bmjopen-2020-037854.
• Hassan, Cesare; Antonelli, Giulio; Dumonceau, Jean-Marc; Regula, Jaroslaw; Bretthauer, Michael & Chaussade, Stanislas [Show all 21 contributors for this article] (2020). Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2020. Endoscopy. ISSN 0013-726X. 52(8), p. 687–700. doi: 10.1055/a-1185-3109.
• Helsingen, Lise M.; Refsum, Erle; Gjøstein, Dagrun Kyte; Løberg, Magnus; Bretthauer, Michael & Kalager, Mette [Show all 7 contributors for this article] (2020). The COVID-19 pandemic in Norway and Sweden – threats, trust, and impact on daily life: a comparative survey. BMC Public Health. ISSN 1471-2458. 20:1597, p. 1–10. doi: 10.1186/s12889-020-09615-3. Full text in Research Archive
• Buskermolen, Maaike; Cenin, Dayna R; Helsingen, Lise M.; Guyatt, Gordon; Vandvik, Per Olav & Haug, Ulrike [Show all 8 contributors for this article] (2019). Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. The BMJ. ISSN 1756-1833. 367, p. 1–11. doi: 10.1136/bmj.l5383.
• Jodal, Henriette C.; Helsingen, Lise M.; Anderson, Joseph C.; Lytvyn, Lyubov; Vandvik, Per Olav & Emilsson, Louise (2019). Colorectal cancer screening with faecal testing, sigmoidoscopy or colonoscopy: a systematic review and network meta-analysis. BMJ Open. ISSN 2044-6055. 9(10), p. 1–18. doi: 10.1136/bmjopen-2019-032773.
• Helsingen, Lise M.; Vandvik, Per Olav; Jodal, Henriette C.; Agoritsas, Thomas; Lytvyn, Lyubov & Anderson, Joseph C. [Show all 21 contributors for this article] (2019). Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: A clinical practice guideline. The BMJ. ISSN 1756-1833. 367:I5515, p. 1–16. doi: 10.1136/bmj.l5515. Show summary

  Abstract CLINICAL QUESTION: Recent 15-year updates of sigmoidoscopy screening trials provide new evidence on the effectiveness of colorectal cancer screening. Prompted by the new evidence, we asked: "Does colorectal cancer screening make an important difference to health outcomes in individuals initiating screening at age 50 to 79? And which screening option is best?" CURRENT PRACTICE: Numerous guidelines recommend screening, but vary on recommended test, age and screening frequency. This guideline looks at the evidence and makes recommendations on screening for four screening options: faecal immunochemical test (FIT) every year, FIT every two years, a single sigmoidoscopy, or a single colonoscopy. RECOMMENDATIONS: These recommendations apply to adults aged 50-79 years with no prior screening, no symptoms of colorectal cancer, and a life expectancy of at least 15 years. For individuals with an estimated 15-year colorectal cancer risk below 3%, we suggest no screening (weak recommendation). For individuals with an estimated 15-year risk above 3%, we suggest screening with one of the four screening options: FIT every year, FIT every two years, a single sigmoidoscopy, or a single colonoscopy (weak recommendation). With our guidance we publish the linked research, a graphic of the absolute harms and benefits, a clear description of how we reached our value judgments, and linked decision aids. HOW THIS GUIDELINE WAS CREATED: A guideline panel including patients, clinicians, content experts and methodologists produced these recommendations using GRADE and in adherence with standards for trustworthy guidelines. A linked systematic review of colorectal cancer screening trials and microsimulation modelling were performed to inform the panel of 15-year screening benefits and harms. The panel also reviewed each screening option's practical issues and burdens. Based on their own experience, the panel estimated the magnitude of benefit typical members of the population would value to opt for screening and used the benefit thresholds to inform their recommendations. THE EVIDENCE: Overall there was substantial uncertainty (low certainty evidence) regarding the 15-year benefits, burdens and harms of screening. Best estimates suggested that all four screening options resulted in similar colorectal cancer mortality reductions. FIT every two years may have little or no effect on cancer incidence over 15 years, while FIT every year, sigmoidoscopy, and colonoscopy may reduce cancer incidence, although for FIT the incidence reduction is small compared with sigmoidoscopy and colonoscopy. Screening related serious gastrointestinal and cardiovascular adverse events are rare. The magnitude of the benefits is dependent on the individual risk, while harms and burdens are less strongly associated with cancer risk. UNDERSTANDING THE RECOMMENDATION: Based on benefits, harms, and burdens of screening, the panel inferred that most informed individuals with a 15-year risk of colorectal cancer of 3% or higher are likely to choose screening, and most individuals with a risk of below 3% are likely to decline screening. Given varying values and preferences, optimal care will require shared decision making.

• Juul, Frederik Emil; Garborg, Kjetil Kjeldstad; Bretthauer, Michael; Skudal, Hilde Kristin; Oines, Mari N. & Wiig, Håvard [Show all 16 contributors for this article] (2018). Fecal microbiota transplantation for primary Clostridium difficile infection. New England Journal of Medicine. ISSN 0028-4793. 378(26), p. 2535–2537. doi: 10.1056/NEJMc1803103. Full text in Research Archive
• Øines, Mari Nanna; Helsingen, Lise M.; Bretthauer, Michael & Emilsson, Louise (2017). Epidemiology and risk factors of colorectal polyps. Baillière's Best Practice & Research : Clinical Gastroenterology. ISSN 1521-6918. 31(4), p. 419–424. doi: 10.1016/j.bpg.2017.06.004.
• Siemieniuk, Reed A.C.; Harris, Ian A.; Agoritsas, Thomas; Poolman, Rudolf W.; Romina, Brignardello-Petersen & Van De Velde, Stijn [Show all 18 contributors for this article] (2017). Arthroscopic surgery for degenerative knee arthritis and meniscal tears: a clinical practice guideline. The BMJ. ISSN 1756-1833. 357. doi: 10.1136/bmj.j1982.

View all works in Cristin

• Gantzel, Rasmus; Wieszczy, Paulina; Refsum, Erle; Jess, Tine; Larsen, Lone & Bretthauer, Michael [Show all 11 contributors for this article] (2023). Prognostic models for colorectal cancer incidence and mortality in patients with inflammatory bowel disease. Cochrane Database of Systematic Reviews. ISSN 1469-493X. doi: 10.1002/14651858.CD015434.
• Helsingen, Lise Mørkved; Løberg, Magnus; Bretthauer, Michael & Kalager, Mette (2022). Reply to: Letter to the Editor regarding "Covid-19 transmission in fitness centers in Norway-a randomized trial". BMC Public Health. ISSN 1471-2458. 22(1). doi: 10.1186/s12889-022-14799-x.
• Øverenget, Einar; Kalager, Mette; Grødeland, Gunnveig; Olsvik, Ørjan; Nylund, Anna & Løberg, Magnus [Show all 8 contributors for this article] (2022). Når smittevern blir uforståelig. Dagensnæringsliv.
• Bretthauer, Michael; Helsingen, Lise Mørkved; Kalager, Mette; Vandvik, Per Olav; Agoritsas, Thomas & Guyatt, Gordon (2020). The future of colorectal cancer screening: Parentalism or shared decision-making? CMAJ - Canadian Medical Association Journal. ISSN 0820-3946. 192(18). doi: 10.1503/cmaj.74839.
• Helsingen, Lise M.; Vandvik, Per Olav; Jodal, Henriette C.; Murphy, Silje Bjerkelund; Heen, Anja Fog & Kalager, Mette [Show all 7 contributors for this article] (2019). Tarmkreftscreening, eller ikke? Tidsskrift for Den norske legeforening. ISSN 0029-2001. 139(15). doi: 10.4045/tidsskr.19.0323.
• Refsum, Erle; Helsingen, Lise M.; Jodal, Henriette Cecilie; Løberg, Magnus; Høstmælingen, Njål & Kalager, Mette (2019). Personvern – en hinderløype. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 139(4), p. 1–3. doi: 10.4045/tidsskr.19.0077.
• Juul, Frederik Emil; Garborg, Kjetil Kjeldstad; Bretthauer, Michael; Kalager, Mette; Midtvedt, Tore & Furholm, Siv [Show all 17 contributors for this article] (2018). Fecal microbiota transplantation versus antibiotics for primary Clostridium difficile infection - a multicenter, randomized proof-of-concept trial.
• Kalager, Mette; Hagen, Eirik M. & Helsingen, Lise M. (2016). Farlig forretning på frykt. Dagens næringsliv. ISSN 0803-9372. 127(278), p. 30–30.
• Helsingen, Lise M. (2015). Ett år som medisinsk redaktør. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 135. doi: 10.4045/tidsskr.15.0851.

View all works in Cristin